Institut Pasteur

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Universite Paris Cité

Fondation Imagine

Gerard Eberl

Lucie Peduto

Ivo Gomperts Boneca

Christophe Brezillon

Djahida Bouskra

Philippe J Sansonetti

David Bikard

Pamela Schnupf

Valerie Gaboriau-Routhiau

Nadine Cerf Bensussan

The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an Olevel inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.

Method of culturing segmented filamentous bacteria in vitro

The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the ablation of ADAM12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.

ADAM12 inhibitors and their use against inflammation-induced fibrosis

Methods and products for modulating the lymphoid system, especially intestinal homeostasis between intestinal lymphoid tissues and gut flora using ligands for NOD1 and/or CCR6.

Method for inducing lymphoid tissue and modulating intestinal homeostasis

Growing community of inventors

Paris, France

Gerard Eberl